Navigating Regulatory Complexity in Biocompatibility, Hemo-compatibility & Toxicology
02 Oct 2025
As regulations continue to change, our knowledge of compliance and biological evaluation in the MedTech sector must develop accordingly. Driving our understanding on this subject to offer critical insights into the recent regulatory changes shaping ISO 10993-1, ISO 10993-18, and the expected ISO 10993-17 revisions. These updates have sparked a shift in expectations around biological safety, posing challenges—but also opportunities—for regulatory strategists, manufacturers, and technical specialists.
Introduction: The New Complexity
Biocompatibility assessments are no longer a “simple” checklist. Regulatory interpretations are becoming increasingly inconsistent across markets, driven by:
- Evolving international standards
- Expanded testing protocols
- Multiple rounds of agency feedback
- Delays in development and approvals
Today, understanding and adapting to these requirements is essential to sustain progress and ensure consistency throughout the entire product lifecycle.
What the Industry Is Seeing
Let’s delve into the emerging trends and standard-specific shifts categorized under Biocompatibility, Toxicology, and Hemocompatibility.
Biocompatibility
| Aspect | Past Practice | Current Expectation |
| Material Info | List of patient-contacted materials/components | Full material characterization per ISO 10993-1:2018 Clause 6 & ISO 10993-18:2020 Clause 5.2.2 |
| Clinical Data | Basic clinical data collection | Analysis relevant to biological safety and risk of adverse events |
| Lifecycle Evaluation | Toxicological testing considered adequate | Chemistry and biology of materials must show no negative impact across storage, temperature, use |
This signals a move toward holistic lifecycle evaluation, where chemistry and biology are assessed not only at initial validation but across every environmental interaction the product may face.
Toxicology
| Area of Focus | Previous Stance | Current Requirement |
| Inorganic Testing | Agencies accepted TRA for sensitization/irritation | Shift to direct evaluations with Dermal Safety Threshold (DST) and inorganic sensitivity data |
| Reproductive/Developmental Toxicity | Rarely considered, especially in pregnant populations | Active evaluation required—even for prenatal exposure scenarios |
| Margin of Safety (MOS) | MOS > 1 assumed protective | Concerns now flagged for MOS between 1 and 10; demands more evidence |
| Surrogate Usage | Surrogates broadly accepted | Agencies require more information when using surrogates, especially with limited toxicity data |
This growing emphasis on reproductive health affects and precise MOS interpretation calls for toxicologists to revisit risk assumptions made in prior dossiers.
Hemocompatibility
In Vivo Testing
- Past: Low trust in in-vivo results
- Now: Accepted only when models closely mimic intended device application
In Vitro Testing
| Method | Traditional Protocols | Modern Testing Needs |
| Platelet Reactivity & PIT Coagulation | ASTM F2488, ASTM F2382 | New test loops and models designed specifically for ISO 10993-1 hemolysis and coagulation evaluation |
This marks a strategic evolution toward application-specific models that can replicate blood-contact environments with greater reliability.
Strategic Takeaways
To stay ahead of this shifting regulatory terrain, here are actionable strategies for your teams:
- Conduct gap analysis across your biocompatibility and toxicology files, aligning with the latest ISO clauses.
- Embrace lifecycle-based chemistry evaluations to reduce the risk of late-stage non-compliance.
- Prepare robust surrogate justification reports that address data limitations transparently.
- Develop adaptive hemo-compatibility models customized to your product’s intended use.
- Collaborate with CROs and regulators early to fine-tune testing frameworks and reduce feedback loops.
Redefining Compliance in the 21st Century
Regulators now request more explicitly stated biological information and are gradually warming to new blood compatibility methods, especially those enhancing ISO 10993-4 testing protocols. For TS Quality & Engineering, this is not just a compliance hurdle—it’s an opportunity to showcase innovation, resilience, and technical leadership.
The road ahead is defined by strategic foresight, evidence-driven documentation, and intelligent testing models. Let’s drive regulatory alignment not just reactively—but proactively, together.
Reference: Malik, S., 2025. Recent Regulatory Changes for Biocompatibility, Hemocompatibility & Toxicology. Medtronic. Presented at RAPS Euro Convergence 2025.
